Nuvation Bio Inc (NYSE:NUVB) has a beta value of 1.45 and has seen 0.73 million shares traded in the recent trading session. The company, currently valued at $580.84M, closed the recent trade at $1.72 per share which meant it lost -$0.1 on the day or -5.77% during that session. The NUVB stock price is -130.81% off its 52-week high price of $3.97 and 0.58% above the 52-week low of $1.71. If we look at the company’s 10-day average daily trading volume, we find that it stood at 2.13 million shares traded. The 3-month trading volume is 2.54 million shares.
The consensus among analysts is that Nuvation Bio Inc (NUVB) is Buy stock at the moment, with a recommendation rating of 1.00. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 4 have rated it as a Hold, with 4 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.12.
Nuvation Bio Inc (NYSE:NUVB) trade information
Sporting -5.77% in the red today, the stock has traded in the red over the last five days, with the highest price hit on recent trading when the NUVB stock price touched $1.72 or saw a rise of 15.69%. Year-to-date, Nuvation Bio Inc shares have moved -35.53%, while the 5-day performance has seen it change -12.50%. Over the past 30 days, the shares of Nuvation Bio Inc (NYSE:NUVB) have changed -12.94%. Short interest in the company has seen 28.39 million shares shorted with days to cover at 9.84.
Wall Street analysts have a consensus price target for the stock at $6, which means that the shares’ value could jump 71.33% from the levels at last check today.. The projected low price target is $5.0 while the price target rests at a high of $10.0. In that case, then, we find that the latest price level in today’s session is -481.4% off the targeted high while a plunge would see the stock gain -190.7% from the levels at last check today..
Nuvation Bio Inc (NUVB) estimates and forecasts
The company’s shares have lost -30.57% over the past 6 months. Revenue growth from the last financial year stood is estimated to be 72.24%.
6 analysts offering their estimates for the company have set an average revenue estimate of 416.67k for the current quarter. 6 have an estimated revenue figure of 416.67k for the next ending quarter.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -49.14% over the past 5 years. Earnings growth for 2025 is a modest 73.12% while over the next 5 years, the company’s earnings are expected to increase by 37.20%.
NUVB Dividends
Nuvation Bio Inc is expected to release its next earnings report on 2025-Mar-05 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Nuvation Bio Inc (NYSE:NUVB)’s Major holders
Insiders own 26.68% of the company shares, while shares held by institutions stand at 58.96% with a share float percentage of 80.41%. Investors are also buoyed by the number of investors in a company, with Nuvation Bio Inc having a total of 212.0 institutions that hold shares in the company. The top two institutional holders are FMR LLC with over 28.82 million shares worth more than $84.16 million. As of 2024-06-30, FMR LLC held 11.7767% of shares outstanding.
The other major institutional holder is ECOR1 CAPITAL, LLC, with the holding of over 19.21 million shares as of 2024-06-30. The firm’s total holdings are worth over $56.09 million and represent 7.8491% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund . As of Jan 31, 2025 , the former fund manager holds about 4.58% shares in the company for having 15.47 shares of worth $26.6 million while later fund manager owns 8.96 shares of worth $15.41 million as of Dec 31, 2024 , which makes it owner of about 2.65% of company’s outstanding stock.
